

# Curriculum Vitae

## Personalia

Name : Deryck Olivier Maurice Martin  
Birth place and date : Ghent, June 4th 1976  
Address : Joe Englishstraat 2, 8000 Brugge, Belgium  
Email : [Olivier.deryck@azsintjan.be](mailto:Olivier.deryck@azsintjan.be)  
Civil status : unmarried  
Nationality : Belgian

## Graduations

### **College**

1988-1994: Latin-Mathematics Sint-Aloysiuscollege Ninove

### **Academical training**

1994-2001: Medicine University of Leuven with  
Medical training in pediatrics, University Hospitals Leuven, Belgium  
Medical training in Obstetrics and Gynaecology, Forth Park Hospital Kirkcaldy  
(Edinburgh), Scotland  
Medical training in Internal Medicine, Sint-Andriesziekenhuis Tielt, Belgium  
Medical training in Surgery, ASZ Aalst, Belgium  
Additional course Neurosurgery  
Certificate Medical English CLT  
Certificate Medical French CLT

June 28th 2001: academical degree of Medical Doctor magna cum laude University of Leuven

2001: Paper: Role of biomarkers in the prognosis of status epilepticus (Promotor Prof Dr W Van Paesschen, University of Leuven)

### **Neurology training 2001-2006**

- 2001-2003: Neurology resident University Hospitals Leuven, training in clinical neurology, including 4 months of specialized training in Multiple Sclerosis in National MS Institute Melsbroek, Prof Dr W. Robberecht
- 2003-2005: Neurology resident AZ St Jan AV Brugge, training in clinical neurology and neurophysiology, Dr I. Dehaene
- 2006: Neurology resident University Hospitals Leuven, training in clinical neurology, Prof Dr W. Robberecht
- June 17th 2006: academical degree of specialist in Neurology, University of Leuven, registration and accreditation with the National Institute of Health and Disability Insurance (RIZIV), nr 1-76186-63-770

## **Additional courses / certificates**

### **MEET (MS Educational European Talent Network) project:**

- 10-11/12/2014: causes, pathogenesis and diagnosis in MS. San Raffaele Hospital Milan
- 29-30/04/2015: Therapeutic Landscape and Biomarkers in MS: CEMCAT Barcelona
- 12-13/11/2015: Future therapies, symptomatic therapies and recovery in MS: Heinrich-Heine University Düsseldorf
- 23-27/11/2016: clinical stage at CEMCAT-MRI Unit Vall d'Hebron Hospital Barcelona (sup Alex Rovira)

MS specialist according to Belgian criteria

Accreditation Modified Rankin Scale, NIHSS, Barthel index, GCS, extended Glasgow outcome scale, revised Hamilton Rating scale for depression, European quality of life, EDSS, ADAS-Cog, ADCS-ADL, NIH-GCP, UPDRS, C-SSRS

## **Professional positions**

- **Current position:**  
Full time Neurologist, Dept of Neurology and Center for cognitive disorders AZ Sint-Jan Brugge-Oostende AV, Ruddershove 10, 8000 Brugge, Belgium.  
  
Stagemeester Neurology from 23/06/2020, accreditation for 6 Neurology trainees
- From 01/10/2006 till 1/10/2007: Consultant Neurology HHart Ziekenhuis Roeselare-Menen, Belgium
- From 2003 till now: Lecturer Neuropathology and neuroanatomy Hogeschool Vives Campus Brugge
- Secretary cel extern beleid (CEB) AZ St Jan AV, Brugge
- Medical student coördinator Neurology University of Leuven 2006-2007

## **Peer reviewed publications and posters, published as abstracts (authorship and corporate authorship)**

1. Patients carrying the mutation p.R406W in MAPT present with non-conforming phenotypic spectrum.  
Gossye H, Van Mossevelde S, Sieben A, Bjerke M, Van de Craen EH, van der Zee J, De Deyn PP, De Bleecker J, Versijpt J, van den Ende J, **Deryck O**, Bourgeois P, Bier JC, Goethals M, Vandenberghe R, Engelborghs S, Van Broeckhoven C.  
**Brain.** **2022 Sep 29:awac362.** doi: 10.1093/brain/awac362. Online ahead of print. PMID: 36171642
2. Diagnostic Performance of Automated MRI Volumetry by icobrain dm for Alzheimer's Disease in a Clinical Setting: A REMEMBER Study.  
Wittens MMJ, Sima DM, Houbrechts R, Ribbens A, Niemantsverdriet E, Fransen E, Bastin C, Benoit F, Bergmans B, Bier JC, De Deyn PP, **Deryck O**, Hanseeuw B,

Ivanoiu A, Lemper JC, Mormont E, Picard G, de la Rosa E, Salmon E, Segers K, Sieben A, Smeets D, Struyfs H, Thiery E, Tournoy J, Triau E, Vanbinst AM, Versijpt J, Bjerke M, Engelborghs S.

**J Alzheimers Dis.** 2021;83(2):623-639. doi: 10.3233/JAD-210450.

3. Contribution of homozygous and compound heterozygous missense mutations in VWA2 to Alzheimer's disease. Hoogmartens J, Hens E, Engelborghs S, Vandenberghe R, De Deyn PP, Cacace R, Van Broeckhoven C; **BELNEU Consortium (oa Deryck O).** **Neurobiol Aging.** 2021 Mar;99:100.e17-100.e23. doi: 10.1016/j.neurobiolaging.2020.09.009. Epub 2020 Sep 12. PMID: 33023779
4. Practices and opinions about disclosure of the diagnosis of Alzheimer's disease to patients with MCI or dementia: a survey among Belgian medical experts in the field of dementia. Mormont E, Bier JC, Bruffaerts R, Cras P, De Deyn P, **Deryck O**, Engelborghs S, Petrovic M, Picard G, Segers K, Thiery E, Versijpt J, Hanseeuw B. **Acta Neurol Belg.** 2020 Oct;120(5):1157-1163. doi: 10.1007/s13760-020-01448-6. Epub 2020 Jul 26. PMID: 32715405
5. Amyloid- $\beta$ 1-43 cerebrospinal fluid levels and the interpretation of APP, PSEN1 and PSEN2 mutations. Perrone F, Bjerke M, Hens E, Sieben A, Timmers M, De Roeck A, Vandenberghe R, Sleegers K, Martin JJ, De Deyn PP, Engelborghs S, van der Zee J, Van Broeckhoven C, Cacace R; **BELNEU Consortium (oa Deryck O).** **Alzheimers Res Ther.** 2020 Sep 11;12(1):108. doi: 10.1186/s13195-020-00676-5. PMID: 32917274
6. Ofatumumab versus Teriflunomide in Multiple Sclerosis. Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; **ASCLEPIOS I** and **ASCLEPIOS II Trial Groups.** **N Engl J Med.** 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246.
7. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). Butzkueven H, Kappos L, Wiendl H, Trojano M, Spelman T, Chang I, Kasliwal R, Jaitly S, Campbell N, Ho PR, Licata S; **Tysabri Observational Program (TOP) Investigators.** **J Neurol Neurosurg Psychiatry.** 2020 Jun;91(6):660-668. doi: 10.1136/jnnp-2019-322326.
8. Dementia, End of Life, and Euthanasia: A Survey Among Dementia Specialists Organized by the Belgian Dementia Council. Picard G, Bier JC, Capron I, De Deyn PP, **Deryck O**, Engelborghs S, Hanseeuw B, Lemper JC, Mormont E, Petrovic M, Salmon E, Segers K, Sieben A, Thiery E, Ventura M, Versijpt J, Ivanoiu A. **J Alzheimers Dis.** 2019;69(4):989-1001. doi: 10.3233/JAD-181277.
9. Loss of DPP6 in neurodegenerative dementia: a genetic player in the dysfunction of neuronal excitability. Cacace R, Heeman B, Van Mossevelde S, De Roeck A, Hoogmartens J, De Rijk P, Gossye H, De Vos K, De Coster W, Strazisar M, De

Baets G, Schymkowitz J, Rousseau F, Geerts N, De Pooter T, Peeters K, Sieben A, Martin JJ, Engelborghs S, Salmon E, Santens P, Vandenbergh R, Cras P, P De Deyn P, C van Swieten J, M van Duijn C, van der Zee J, Sleegers K, Van Broeckhoven C; BELNEU Consortium (***oa Deryck O.***). **Acta Neuropathol.** 2019 Jun;137(6):901-918. doi: 10.1007/s00401-019-01976-3.

10. No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients. Baradaran-Heravi Y, Dillen L, Nguyen HP, Van Mossevelde S, Baets J, De Jonghe P, Engelborghs S, De Deyn PP, Vandenberghe M, Vandenberghe R, Van Damme P, Cras P, Salmon E, Synofzik M, Heutink P, Wilke C, Simon-Sanchez J, Rojas-Garcia R, Turon-Sans J, Lleó A, Illán-Gala I, Clarimón J, Borroni B, Padovani A, Pastor P, Diez-Fairen M, Aguilar M, Gelpi E, Sanchez-Valle R, Borrego-Ecija S, Matej R, Parobkova E, Nacmias B, Sorbi S, Bagnoli S, de Mendonça A, Ferreira C, Fraidakis MJ, Diehl-Schmid J, Alexopoulos P, Almeida MR, Santana I, Van Broeckhoven C, van der Zee J; BELNEU Consortium (***oa Deryck O.***), EU EOD Consortium. **Neurobiol Aging.** 2018 Sep;69:293.e9-293.e11. doi:10.1016/j.neurobiolaging.2018.05.005. Epub 2018 May 23.
11. A Retrospective Belgian Multi-Center MRI Biomarker Study in Alzheimer's Disease (REMEMBER). Niemantsverdriet E, Ribbens A, Bastin C, Benoit F, Bergmans B, Bier JC, Bladt R, Claes L, De Deyn PP, **Deryck O**, Hanseeuw B, Ivanoiu A, Lemper JC, Mormont E, Picard G, Salmon E, Segers K, Sieben A, Smeets D, Struyfs H, Thiery E, Tournoy J, Triau E, Vanbinst AM, Versijpt J, Bjerke M, Engelborghs S. **J Alzheimers Dis.** 2018;63(4):1509-1522. doi: 10.3233/JAD-171140.
12. Clinical variability and onset age modifiers in an extended Belgian GRN founder family. Wauters E, Van Mossevelde S, Sleegers K, van der Zee J, Engelborghs S, Sieben A, Vandenberghe R, Philtjens S, Van den Broeck M, Peeters K, Cuijt I, De Coster W, Van Langenhove T, Santens P, Ivanoiu A, Cras P, De Bleecker JL, Versijpt J, Crols R, De Klippe N, Martin JJ, De Deyn PP, Cruts M, Van Broeckhoven C; Belgian Neurology (BELNEU) Consortium (***oa Deryck O.***). **Neurobiol Aging.** 2018 Jul;67:84-94. doi: 10.1016/j.neurobiolaging.2018.03.007. Epub 2018 Mar 10.
13. An intronic VNTR affects splicing of ABCA7 and increases risk of Alzheimer's disease. De Roeck A, Duchateau L, Van Dongen J, Cacace R, Bjerke M, Van den Bossche T, Cras P, Vandenberghe R, De Deyn PP, Engelborghs S, Van Broeckhoven C, Sleegers K; BELNEU Consortium (***oa Deryck O.***). **Acta Neuropathol.** 2018 Jun;135(6):827-837. doi: 10.1007/s00401-018-1841-z. Epub 2018 Mar 27.
14. Rare nonsynonymous variants in SORT1 are associated with increased risk for frontotemporal dementia. Philtjens S, Van Mossevelde S, van der Zee J, Wauters E, Dillen L, Vandenberghe M, Vandenberghe R, Ivanoiu A, Sieben A, Willems C, Benussi L, Ghidoni R, Binetti G, Borroni B, Padovani A, Pastor P, Diez-Fairen M, Aguilar M, de Mendonça A, Miltenberger-Miltényi G, Hernández I, Boada M, Ruiz A, Nacmias B, Sorbi S, Almeida MR, Santana I, Clarimón J, Lleó A, Frisoni GB, Sanchez-Valle R, Lladó A, Gómez-Tortosa E, Gelpi E, Van den Broeck M, Peeters K, Cras P, De Deyn PP, Engelborghs S, Cruts M, Van Broeckhoven C; BELNEU Consortium (***oa Deryck O.***); EU EOD Consortium.

**Neurobiol Aging.** 2018 Jun;66:181.e3-181.e10.  
doi:10.1016/j.neurobiolaging.2018.02.011. Epub 2018 Feb 17.

15. A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis. Laureys G, Willekens B, Vanopdenbosch L, **Deryck O**, Selleslag D, D'Haeseleer M, De Becker A, Dubois B, Dierickx D, Perrotta G, De Wilde V, van Pesch V, Straetmans N, Dive D, Beguin Y, Van Wijmeersch B, Theunissen K, Kerre T, Van de Velde A.  
**Acta Neurol Belg.** 2018 Jun;118(2):161-168. doi: 10.1007/s13760-018-0905-0. Epub 2018 Mar 13.
16. Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort. Verheijen J, van der Zee J, Gijselinck I, Van den Bossche T, Dillen L, Heeman B, Gómez-Tortosa E, Lladó A, Sanchez-Valle R, Graff C, Pastor P, Pastor MA, Benussi L, Ghidoni R, Binetti G, Clarimon J, de Mendonça A, Gelpi E, Tsolaki M, Diehl-Schmid J, Nacmias B, Almeida MR, Borroni B, Matej R, Ruiz A, Engelborghs S, Vandenberghe R, De Deyn PP, Cruts M, Van Broeckhoven C, Sleegers K; BELNEU Consortium (**oa Deryck O**); EU EOD Consortium.  
**Neurobiol Aging.** 2018 Feb;62:245.e1-245.e7.  
doi:10.1016/j.neurobiolaging.2017.10.012. Epub 2017 Oct 25.
17. Alzheimer's disease and driving: review of the literature and consensus guideline from Belgian dementia experts and the Belgian road safety institute endorsed by the Belgian Medical Association. Versijpt J, Tant M, Beyer I, Bier JC, Cras P, De Deyn PP, De Wit P, **Deryck O**, Hanseeuw B, Lambert M, Lemper JC, Mormont E, Petrovic M, Picard G, Salmon E, Segers K, Sieben A, Thiery E, Tournoy J, Vandewoude M, Ventura M, Verschraegen J, Engelborghs S, Goffin T, Deneyer M, Ivanoiu A.  
**Acta Neurol Belg.** 2017 Dec;117(4):811-819. doi: 10.1007/s13760-017-0840-5. Epub 2017 Oct 5. Review.
18. NEK1 genetic variability in a Belgian cohort of ALS and ALS-FTD patients. Nguyen HP, Van Mossevelde S, Dillen L, De Bleecker JL, Moisse M, Van Damme P, Van Broeckhoven C, van der Zee J; BELNEU Consortium (**oa Deryck O**).  
**Neurobiol Aging.** 2018 Jan;61:255.e1-255.e7.  
doi:10.1016/j.neurobiolaging.2017.08.021. Epub 2017 Aug 31.
19. Clinical Evidence of Disease Anticipation in Families Segregating a C9orf72 Repeat Expansion. Van Mossevelde S, van der Zee J, Gijselinck I, Sleegers K, De Bleecker J, Sieben A, Vandenberghe R, Van Langenhove T, Baets J, **Deryck O**, Santens P, Ivanoiu A, Willems C, Bäumer V, Van den Broeck M, Peeters K, Mattheijssens M, De Jonghe P, Cras P, Martin JJ, Cruts M, De Deyn PP, Engelborghs S, Van Broeckhoven C; Belgian Neurology (BELNEU) Consortium.  
**JAMA Neurol.** 2017 Apr 1;74(4):445-452.  
doi:10.1001/jamaneurol.2016.4847.
20. Investigating the role of ALS genes CHCHD10 and TUBA4A in Belgian FTD-ALS spectrum patients. Perrone F, Nguyen HP, Van Mossevelde S, Moisse M, Sieben A, Santens P, De Bleecker J, Vandenbulcke M, Engelborghs S, Baets J, Cras P, Vandenberghe R, De Jonghe P, De Deyn PP, Martin JJ, Van Damme P, Van Broeckhoven C, van der Zee J; Belgian Neurology consortium (**oa Deryck O**).

**Neurobiol Aging.** 2017 Mar;51:177.e9-177.e16.  
doi:10.1016/j.neurobiolaging.2016.12.008. Epub 2016 Dec 21.

21. TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. van der Zee J, Gijselinck I, Van Mossevelde S, Perrone F, Dillen L, Heeman B, Bäumer V, Engelborghs S, De Bleecker J, Baets J, Gelpi E, Rojas-García R, Clarimón J, Lleó A, Diehl-Schmid J, Alexopoulos P, Perneczky R, Synofzik M, Just J, Schöls L, Graff C, Thonberg H, Borroni B, Padovani A, Jordanova A, Sarafov S, Tournev I, de Mendonça A, Miltenberger-Miltényi G, Simões do Couto F, Ramirez A, Jessen F, Heneka MT, Gómez-Tortosa E, Danek A, Cras P, Vandenberghe R, De Jonghe P, De Deyn PP, Sleegers K, Cruts M, Van Broeckhoven C, Goeman J, Nuytten D, Smets K, Robberecht W, Damme PV, Bleecker J, Santens P, Dermaut B, Versijpt J, Michotte A, Ivanoiu A, **Deryck O**, Bergmans B, Delbeck J, Bruylants M, Willems C, Salmon E, Pastor P, Ortega-Cubero S, Benussi L, Ghidoni R, Binetti G, Hernández I, Boada M, Ruiz A, Sorbi S, Nacmias B, Bagnoli S, Sorbi S, Sanchez-Valle R, Llado A, Santana I, Rosário Almeida M, Frisoni GB, Maetzler W, Matej R, Fraidakis MJ, Kovacs GG, Fabrizi GM, Testi S.  
**Hum Mutat.** 2017 Mar;38(3):297-309. doi: 10.1002/humu.23161. Epub 2017 Jan 19.
22. Pearls & Oy-sters: Visual agnosia: An overlooked cortical sign. Bergmans B, **Deryck O**, Bruffaerts R.  
**Neurology** 2016 Nov 8;87(19):e237-e238. No abstract available.
23. Phenotypic characteristics of Alzheimer patients carrying an ABCA7 mutation. Van den Bossche T, Sleegers K, Cuyvers E, Engelborghs S, Sieben A, De Roeck A, Van Cauwenbergh C, Vermeulen S, Van den Broeck M, Laureys A, Peeters K, Mattheijssens M, Vandebulcke M, Vandenberghe R, Martin JJ, De Deyn PP, Cras P, Van Broeckhoven C; Belgian Neurology Consortium (*oa Deryck O*).  
**Neurology** 2016 Jun 7;86(23):2126-33. doi: 10.1212/WNL.0000000000002628. Epub 2016 Apr 1.
24. Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort. Van Mossevelde S, van der Zee J, Gijselinck I, Engelborghs S, Sieben A, Van Langenhove T, De Bleecker J, Baets J, Vandebulcke M, Van Laere K, Ceyssens S, Van den Broeck M, Peeters K, Mattheijssens M, Cras P, Vandenberghe R, De Jonghe P, Martin JJ, De Deyn PP, Cruts M, Van Broeckhoven C; Belgian Neurology consortium (*oa Deryck O*).  
**Brain.** 2016 Feb;139(Pt 2):452-67. doi: 10.1093/brain/awv358. Epub 2015 Dec 15.
25. Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort. Gijselinck I, Van Mossevelde S, van der Zee J, Sieben A, Philtjens S, Heeman B, Engelborghs S, Vandebulcke M, De Baets G, Bäumer V, Cuijt I, Van den Broeck M, Peeters K, Mattheijssens M, Rousseau F, Vandenberghe R, De Jonghe P, Cras P, De Deyn PP, Martin JJ, Cruts M, Van Broeckhoven C; BELNEU Consortium (*oa Deryck O*). **Neurology.** 2015 Dec 15;85(24):2116-25.  
doi: 10.1212/WNL.0000000000002220. Epub 2015 Nov 18.
26. Investigating the role of filamin C in Belgian patients with frontotemporal dementia linked to GRN deficiency in FTLD-TDP brains. Janssens J, Philtjens S,

- Kleinberger G, Van Mossevelde S, van der Zee J, Cacace R, Engelborghs S, Sieben A, Banzhaf-Strathmann J, Dillen L, Merlin C, Cuijt I, Robberecht C, Schmid B, Santens P, Ivanoiu A, Vandenbulcke M, Vandenberghe R, Cras P, De Deyn PP, Martin JJ, Maudsley S, Haass C, Cruts M, Van Broeckhoven C; Belgian Neurology (BELNEU) consortium (**oa Deryck O**).  
**Acta Neuropathol Commun.** 2015 Nov 10;3:68. doi: 10.1186/s40478-015-0246-7.
27. The C9orf72 repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter. Gijselinck I, Van Mossevelde S, van der Zee J, Sieben A, Engelborghs S, De Bleeker J, Ivanoiu A, **Deryck O**, Edbauer D, Zhang M, Heeman B, Bäumer V, Van den Broeck M, Mattheijssens M, Peeters K, Rogaeva E, De Jonghe P, Cras P, Martin JJ, de Deyn PP, Cruts M, Van Broeckhoven C. **Mol Psychiatry.** 2016 Aug;21(8):1112-24. doi: 10.1038/mp.2015.159. Epub 2015 Oct 20.
28. A 22-single nucleotide polymorphism Alzheimer's disease risk score correlates with family history, onset age, and cerebrospinal fluid Aβ42. Sleegers K, Bettens K, De Roeck A, Van Cauwenbergh C, Cuyvers E, Verheyen J, Struyfs H, Van Dongen J, Vermeulen S, Engelborghs S, Vandenbulcke M, Vandenberghe R, De Deyn PP, Van Broeckhoven C; BELNEU consortium (oa **Deryck O**).  
**Alzheimers Dement.** 2015 Dec;11(12):1452-1460.  
doi:10.1016/j.jalz.2015.02.013. Epub 2015 Jun 15.
29. Rare Variants in PLD3 Do Not Affect Risk for Early-Onset Alzheimer Disease in a European Consortium Cohort. Cacace R, Van den Bossche T, Engelborghs S, Geerts N, Laureys A, Dillen L, Graff C, Thonberg H Chiang HH, Pastor P, Ortega-Cubero S, Pastor MA, Diehl-Schmid J, Alexopoulos P, Benussi L, Ghidoni R, Binetti G, Nacmias B, Sorbi S, Sanchez-Valle R, Lladó A, Gelpí E, Almeida MR, Santana I, Tsolaki M, Koutroumani M, Clarimon J, Lleó A, Fortea J, de Mendonça A, Martins M, Borroni B, Padovani A, Matej R, Rohan Z, Vandenbulcke M, Vandenberghe R, De Deyn PP, Cras P, van der Zee J, Sleegers K, Van Broeckhoven C; Belgium Neurology (BELNEU) Consortium (**oa Deryck O**) and the European Early-Onset Dementia (EU EOD) Consortium.  
**Hum Mutat.** 2015 Dec;36(12):1226-35. doi: 10.1002/humu.22908.
30. Pseudotumoral rebound of multiple sclerosis in a pregnant patient after stopping natalizumab. Verhaeghe A, **Deryck OM**, Vanopdenbosch LJ.  
**Mult Scler Relat Disord.** 2014 Mar;3(2):279-81.  
doi:10.1016/j.msard.2013.10.001. Epub 2013 Oct 3.
31. Clinical utility and applicability of biomarker-based diagnostic criteria for Alzheimer's disease: a BeDeCo survey. Bier JC, Verschraegen J, Vandenberghe R, Guillaume B, Picard G, Otte G, Mormont E, Gilles C, Segers K, Sieben A, Thiery E,

- Ventura M, De Deyn P, **Deryck O**, Versijpt J, Salmon E, Engelborghs S, Ivanoiu A.  
**Acta Neurol Belg.** 2015 Dec;115(4):547-55. doi: 10.1007/s13760-014-0423-7. Epub 2015 Jan 10.
32. Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia. Cuyvers E, Bettens K, Philtjens S, Van Langenhove T, Gijselinck I, van der Zee J, Engelborghs S, Vandenbulcke M, Van Dongen J, Geerts N, Maes G, Mattheijssens M, Peeters K, Cras P, Vandenberghe R, De Deyn PP, Van Broeckhoven C, Cruts M, Sleegers K; BELNEU consortium (*oa Deryck O*).  
**Neurobiol Aging.** 2014 Mar;35(3):726.e11-9. doi: 10.1016/j.neurobiolaging.2013.09.009. Epub 2013 Oct 9.
33. MRI characteristics of trigeminal nerve involvement in patients with multiple sclerosis. Swinnen C, Lunsken S, **Deryck O**, Casselman J, Vanopdenbosch L.  
**Mult Scler Relat Disord.** 2013 Jul;2(3):200-3.  
doi: 10.1016/j.msard.2012.12.002. Epub 2013 Jan 10.
34. Distinct clinical characteristics of C9orf72 expansion carriers compared with GRN, MAPT, and nonmutation carriers in a Flanders-Belgian FTLD cohort. Van Langenhove T, van der Zee J, Gijselinck I, Engelborghs S, Vandenberghe R, Vandenbulcke M, De Bleeker J, Sieben A, Versijpt J, Ivanoiu A, **Deryck O**, Willems C, Dillen L, Philtjens S, Maes G, Bäumer V, Van Den Broeck M, Mattheijssens M, Peeters K, Martin JJ, Michotte A, Santens P, De Jonghe P, Cras P, De Deyn PP, Cruts M, Van Broeckhoven C.  
**JAMA Neurol.** 2013 Mar 1;70(3):365-73. doi: 10.1001/2013.jamaneurol.181.
35. Explorative genetic study of UBQLN2 and PFN1 in an extended Flanders-Belgian cohort of frontotemporal lobar degeneration patients. Dillen L, Van Langenhove T, Engelborghs S, Vandenbulcke M, Sarafov S, Tournev I, Merlin C, Cras P, Vandenberghe R, De Deyn PP, Jordanova A, Cruts M, Van Broeckhoven C, van der Zee J; BELNEU consortium (*oa Deryck O*).  
**Neurobiol Aging.** 2013 Jun;34(6):1711.e1-5.  
doi:10.1016/j.neurobiolaging.2012.12.007. Epub 2013 Jan 9.
36. Boosting endogenous neuroprotection in multiple sclerosis: the Association of Inosine and Interferon beta in relapsing- remitting Multiple Sclerosis (ASIIMS) trial. Gonsette RE, Sindic C, D'hooghe MB, De Deyn PP, Medaer R, Michotte A, Seeldrayers P, Guillaume D; ASIIMS study group (*oa Deryck O*).  
**Mult Scler.** 2010 Apr;16(4):455-62. doi: 10.1177/1352458509360547. Epub 2010 Mar 3.
37. Clinical characteristics and long term prognosis in early onset multiple sclerosis. **Deryck O**, Ketelaer P, Dubois B.  
**J Neurol.** 2006 Jun;253(6):720-3. Epub 2006 Mar 6.

## Posters

**Deryck O**, Ketelaer P, Dubois B. Clinical characteristics and disease course in early onset multiple sclerosis. Poster ECTRIMS 2003, abstract Multiple Sclerosis

**Deryck O**, Verhoeven K. Acute asymmetrical cervico-pharyngo-bracial weakness: an unusual presentation of acute motor axonal neuropathy. Poster Neurobelgium 2004, abstract Acta neurological belgica

B.A. Bergmans, R. Bruffaerts, M. Verhalle, L. Vanopdenbosch, K. Verhoeven, A. Van Dycke, **O. Deryck**. Predictive parameters for the effect of botulinum neurotoxin infiltrations in chronic migraine. Poster European Headache and Migraine Trust International Congress 18-21 Sept 2014, Copenhagen, Denmark

B.A. Bergmans, R. Bruffaerts, M. Verhalle, L. Vanopdenbosch, K. Verhoeven, A. Van Dycke, **O. Deryck**. Botulinum toxin infiltration for chronic migraine are efficacious and safe: the Bruges experience.

B. Willekens , V. Van Pesch, M. D'Hooghe, D. Dive , B. Dubois , R. Bouton, M. Cambron , B. Capron , R. Crols , B. Dachy, F. Debruyne, J. Debruyne, D. Decoo, V. Delvaux, **O. Deryck**, M. Dewil, I. Dhollander, A. De Pauw, J.-A. Elosgégi, S. El Sankari, A. Etxeberria Izal, S. Goffette, N. Govers, D. Guillaume, A.-G. Herbaut, N. Jacquemotte, P. Jacquerye, G. Laureys, N. Libbrecht, E. Lommers, F. London, A. Maertens de Noordhout, G. Nagels, K. Peeters, G. Perrotta, R. Reznik, S. Shalchian, C. Swinnen, E. Urbain, K. Van de Velde, D. Verhalle, P. Seeldrayers, and on behalf of the Belgian Study Group for Multiple Sclerosis, BSGMS, Belgium. The BELTRIMS registry: a unique Belgian registry on real-world safety and efficacy data of MS patients treated with new DMTs in Belgium. Poster European Charcot Foundation symposium 2018, Baveno, Italy

## Clinical trials (PI)

- *Alzheimer's disease*: Principal investigator phase III Identity (semagacestat), phase III 3133K1-3001/3133K1-3003 (bapineuzumab), phase III Lu AE58054, phase II/III MK-8931-017 trial, Phase III MK-8931-019 trial, Phase III EMERGE trial, Phase III CREAD II trial, Phase III EVOLVE trial, RAMAN trial, EMBARK trial, AUTONOMY trial
- *Multiple sclerosis*: Principal investigator MT-1303-E04 and MT-1303-E05 phase II clinical trial, Reflexion, ENDORSE, DreaMS phase III open label extension trial and PASSAGE, TOP and PREMIERE registers, PROTEC and MS-NICE observational study (Belgian Study group of Multiple sclerosis), ENSEMBLE (plus), AFFINITY, ASCLEPIOS, ALITHIOS, ARTIOS
- *Migraine*: co-investigator CONQUER, FOCUS, APPRAISE, LAIJ trial, DELIVER,
- Cluster headache: co-investigator ALLEViate

## Review / Editorial board

Reviewer acta neurologica belgica  
Member Advisory board AZ link

**International advisory board** MK-8931-19 study Rome: A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD).

**International advisory board** on patient reported outcomes in MS (Genzyme): ECTRIMS congress London 2016.

## National and international professional memberships

President of Belgian Dementia Council (BeDeCo)  
Member of BELNEU consortium early onset dementia

Member of International Society to Advance Alzheimer's Research and Treatment (ISTAART)

Member of International Society for Frontotemporal Dementias (ISFTD)

Member of Belgian Study Group of Multiple Sclerosis  
Spokesman of the Brilliants in MS group (BiMS)

Member of the Vereniging Vlaamse Neurologen  
Associated member of the Belgian Neurological Society  
Member of Belgische beroepsvereniging Neurologie

Member of the European Neurological Society  
Member of IHS International Headache Society

Board Member of vzw KoMee